OCU410ST
Phase 2/3Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stargardt Disease
Conditions
Stargardt Disease
Trial Timeline
Aug 25, 2023 → Sep 28, 2026
NCT ID
NCT05956626About OCU410ST
OCU410ST is a phase 2/3 stage product being developed by Ocugen for Stargardt Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05956626. Target conditions include Stargardt Disease.
What happened to similar drugs?
0 of 1 similar drugs in Stargardt Disease were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
15
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05956626 | Phase 2/3 | Recruiting |
Competing Products
9 competing products in Stargardt Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MA09-hRPE | Astellas Pharma | Pre-clinical | 26 |
| MA09-hRPE | Astellas Pharma | Phase 1/2 | 32 |
| avacincaptad pegol + Sham | Astellas Pharma | Phase 2 | 35 |
| MA09-hRPE | Astellas Pharma | Phase 1/2 | 32 |
| hESC-RPE | Astellas Pharma | Pre-clinical | 26 |
| SAR422459 | Sanofi | Phase 1/2 | 24 |
| Long term follow up in all patients who received SAR422459 in previous study TDU13583 | Sanofi | Phase 2 | 39 |
| tinlarebant | Belite Bio | Phase 1/2 | 29 |
| Tinlarebant + Placebo | Belite Bio | Phase 3 | 37 |